Bristol Myers Squibb to Acquire Mirati Therapeutics for Up to US$5.8 B
By Lucy Haggerty
Pharma Deals Review: Vol 2023 Issue 10 (Table of Contents)
Published: 12 Oct-2023
DOI: 10.3833/pdr.v2023.i10.2808 ISSN: 1756-7874
Section: Mergers & Acquisitions
Fulltext:
Abstract
In a bid to expand its oncology franchise, Bristol Myers Squibb (BMS) has agreed to acquire Mirati Therapeutics for US$58 per share in cash...
This page is available to subscribers only.
Not a subscriber? Join here
Already Registered? Please login using the top left purple box.
Copyright: © IQVIA 2018
RSS